Mahyar Ajir, DO
Family Medicine · Carlsbad, CANPI 1518999218
Payments from drug & device makers
Across 287 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- AbbVie$670
- Lilly USA, LLC$541
- Bayer$464
- Sanofi-aventis U.S. LLC$284
- plus $3K from 32 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$8,306100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $2,206 |
| GSK | 51 | $1,522 |
| AbbVie(2 entities) | 15 | $670 |
| Lilly USA, LLC | 21 | $541 |
| Bayer | 13 | $464 |
| Sanofi-aventis U.S. LLC | 17 | $284 |
| Merck | 15 | $258 |
| Pfizer | 12 | $241 |
| Edwards Lifesciences | 2 | $217 |
| Eisai Inc. | 6 | $195 |
| Boehringer Ingelheim | 10 | $170 |
| Sanofi Pasteur Inc. | 4 | $155 |
| Seqirus USA Inc | 7 | $146 |
| Exact Sciences | 6 | $144 |
| Amarin Pharma, Inc. | 6 | $139 |
| Amgen | 2 | $129 |
| Abbott | 5 | $86 |
| Novo Nordisk | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Johnson & Johnson | 4 | $63 |
| Boston Scientific | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Dexcom, Inc. | 2 | $51 |
| TMS Neurohealth Centers Inc. | 2 | $44 |
| Topcon Healthcare Solutions, Inc. | 1 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Medtronic | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Neotract Inc. | 1 | $21 |
| Itamar Medical Inc | 1 | $20 |
| Si-bone, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$408
- BREZTRI$379
- AIRSUPRA$371
- FARXIGA$363
- UBRELVY$243
- Kerendia$240
- SAPIEN 3 Ultra RESILIA$172
- AIMOVIG$125
- QULIPTA$125
- Leqembi$124
- MOUNJARO$112
- KISUNLA$111
- TRELEGY ELLIPTA$107
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$100
- FLUZONE QUADRIVALENT$100
- FLUZONE HIGH-DOSE$100
How this compares
$8,310 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 86 | $85,733 |
| EliquisApixaban | 59 | $73,142 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $52,737 |
| OzempicSemaglutide | 40 | $43,359 |
| LinzessLinaclotide | 23 | $36,489 |
| JardianceEmpagliflozin | 27 | $32,770 |
| TradjentaLinagliptin | 28 | $27,215 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $25,817 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $22,561 |
| XareltoRivaroxaban | 15 | $19,888 |
| JanuviaSitagliptin Phosphate | 12 | $18,838 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,206 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,637 |
| MyrbetriqMirabegron | 16 | $10,654 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $10,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,206 | $85,73386 claims |
| PfizerEliquis | $241 | $73,14259 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,522 | $65,37470 claims |
| Boehringer IngelheimJardiance, Tradjenta | $170 | $59,98655 claims |
| Novo NordiskOzempic | $83 | $43,35940 claims |
| AbbVieLinzess | $670 | $36,48923 claims |
| Johnson & JohnsonXarelto | $63 | $19,88815 claims |
| MerckJanuvia | $258 | $18,83812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Carlsbad
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.